Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 2/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330170 | 0.87 | TMPRSS4 (0.51) | TMPRSS4MEN1KMT2A | |
| SCHEMBL331430 | 0.85 | MAPT (0.53) | TMPRSS4MAPTGAASORT1PLAU | |
| SCHEMBL330258 | 0.81 | TMPRSS4 (0.43) | TMPRSS4MAPTGAASORT1PLAU | |
| SCHEMBL330478 | 0.81 | TMPRSS4 (0.43) | TMPRSS4MAPTGAASORT1PLAU | |
| SCHEMBL330623 | 0.77 | MEN1 (0.39) | TMPRSS4MAPTGAASORT1SMN1; SMN2 | |
| SCHEMBL329927 | 0.77 | DHODH (0.54) | MAPTSMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL330102 | 0.76 | TRPV4 (0.45) | — | |
| SCHEMBL330403 | 0.76 | TMPRSS4 (0.55) | TMPRSS4MAPTGAASORT1PLAU | |
| SCHEMBL330057 | 0.76 | LRRK2 (0.48) | TMPRSS4MAPTALDH1A1HTT | |
| SCHEMBL330052 | 0.75 | MAPT (0.39) | TMPRSS4MAPTSORT1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AEROMICS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240360077-A1 | METHODS | AEROMICS, INC. | 2024-10-31 | — | — | US | disclosed |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AEROMICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20220081391-A1 | METHODS | AEROMICS, INC. | 2022-03-17 | — | — | US | disclosed |
| CN-109512805-B | Compounds for the treatment of aquaporin mediated diseases | 埃罗米克斯公司 | 2021-12-31 | — | — | CN | disclosed |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AEROMICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20180334424-A1 | METHODS | AEROMICS, INC. | 2018-11-22 | — | — | US | disclosed |
| EP-2846787-B1 | Compounds for use in the treatment of aquaporin-mediated diseases | AEROMICS INC (US) | 2018-08-29 | — | — | EP | disclosed |
| US-9994514-B2 | Methods of treating cerebral edema and spinal cord edema | AEROMICS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9949991-B2 | Methods of treating aquaporin-mediated conditions | AEROMICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20150342967-A1 | METHODS | AEROMICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150133405-A1 | Methods | AEROMICS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-8263657-B2 | Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-8097759-B2 | Inflammatory cytokine release inhibitor | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1847263-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1844766-A2 | Inhibitors against the production and release of inflammatory cytokines | Institute of Medicinal Molecular Design, Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150342967-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885MAPT 1003/4885GAA 755/4885 |
| US-20180334424-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885MAPT 1003/4885GAA 755/4885 |
| US-12503425-B2 | Methods of treating or controlling cytotoxic cerebral edema | AQP4, AQP1, AQP3 | TMPRSS4 1043/4885MAPT 724/4885GAA 695/4885 |
| US-20220081391-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885MAPT 1003/4885GAA 755/4885 |
| US-20100274051-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1813/4885MAPT 1849/4885GAA 525/4885 |
| US-11084778-B2 | Methods of treating cardiac edema, neuromyelitis optica, and hyponatremia | AQP4, AQP1, AQP3 | TMPRSS4 946/4885MAPT 900/4885GAA 759/4885 |
| US-20080318956-A1 | INFLAMMATORY CYTOKINE RELEASE INHIBITOR | IL1B, NFKBIA, IL1A | TMPRSS4 1647/4885MAPT 2086/4885GAA 618/4885 |
| US-20150133405-A1 | Methods | AQP4, AQP1, AQP3 | TMPRSS4 1257/4885MAPT 1003/4885GAA 755/4885 |
| US-11873266-B2 | Methods of treating or controlling cytotoxic cerebral edema consequent to an ischemic stroke | AQP4, AQP1, AQP3 | TMPRSS4 1444/4885MAPT 549/4885GAA 333/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | TMPRSS4 3292/4885MAPT 2435/4885GAA 954/4885 |
| US-20240360077-A1 | METHODS | AQP4, AQP1, AQP3 | TMPRSS4 1415/4885MAPT 1114/4885GAA 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.